Dr. Bekaii Saab on Immunotherapeutic Options in CRC Beyond PD-1/PD-L1

Tanios Bekaii-Saab, MD
Published: Thursday, Jan 12, 2017


Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses immunotherapeutic options being explored in the treatment landscape of colorectal cancer (CRC) beyond PD-1/PD-L1 agents.

There are other strategies that investigators are exploring in this area aside from the PD-1/PD-L1 inhibitors, Bekaii-Saab explains. Some of these include knocking down the wnt/β-catenin pathway, which could be a more powerful stimulant for the immune system for tumor-infiltrating lymphocytes and is more likely to benefit patients when combined with PD-1/PD-L1 agents. There is a high level of activity there, but there are other pathways still being investigated.

Additionally, he says, there will be a larger subgroup of patients with metastatic CRC who have microsatellite-stable disease that will eventually be eligible for immunotherapy.

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses immunotherapeutic options being explored in the treatment landscape of colorectal cancer (CRC) beyond PD-1/PD-L1 agents.

There are other strategies that investigators are exploring in this area aside from the PD-1/PD-L1 inhibitors, Bekaii-Saab explains. Some of these include knocking down the wnt/β-catenin pathway, which could be a more powerful stimulant for the immune system for tumor-infiltrating lymphocytes and is more likely to benefit patients when combined with PD-1/PD-L1 agents. There is a high level of activity there, but there are other pathways still being investigated.

Additionally, he says, there will be a larger subgroup of patients with metastatic CRC who have microsatellite-stable disease that will eventually be eligible for immunotherapy.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x